Perry A Karsen is Director of Intellia Therapeutics, Inc.. Currently has a direct ownership of 5,000 shares of NTLA, which is worth approximately $71,650. The most recent transaction as insider was on Dec 17, 2020, when has been sold 88,764 shares (Common Stock) at a price of $53.51 per share, resulting in proceeds of $4,749,761. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5K
0% 3M change
0% 12M change
Total Value Held $71,650

PERRY A KARSEN Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 17 2020
SELL
Open market or private sale
$4,749,761 $53.51 p/Share
88,764 Reduced 94.67%
5,000 Common Stock
Dec 17 2020
BUY
Exercise of conversion of derivative security
$1,644,797 $18.53 p/Share
88,764 Added 48.63%
93,764 Common Stock

Also insider at

JNCE
Jounce Therapeutics, Inc. Healthcare
GRPH
Graphite Bio, Inc. Healthcare
PAK

Perry A Karsen

Director
Cambridge, MA

Track Institutional and Insider Activities on NTLA

Follow Intellia Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

News

Receive news related to Intellia Therapeutics, Inc.

Track Activities on NTLA